Epigenetic pathway crosstalk

Epigenetic pathway crosstalk refers to the complex, reciprocal interactions between different epigenetic regulatory mechanisms, such as DNA methylation, histone modifications, and non-coding RNA activity (Cedar & Bergman, 2009). These pathways do not function in isolation; for instance, DNA methyltransferases (DNMTs) often recruit histone deacetylases (HDACs) to promote a repressive chromatin state, while specific histone marks can guide the placement of DNA methylation (Nature Reviews Genetics, 2009). In many diseases, particularly cancer and metabolic disorders, this crosstalk is dysregulated, leading to the silencing of tumor suppressor genes and the activation of oncogenic programs (Frontiers in Cell and Developmental Biology, 2020). Therapeutic strategies often aim to disrupt this crosstalk using combination therapies, such as pairing DNMT inhibitors like decitabine with HDAC inhibitors like vorinostat, to achieve a more robust and durable reprogramming of the epigenome (Nature Reviews Cancer, 2012). This approach is designed to overcome the compensatory mechanisms that often lead to resistance in single-agent epigenetic therapy (PubMed, 2021). Furthermore, the interplay between metabolic intermediates and epigenetic enzymes adds another layer of complexity, where cellular metabolism directly influences the availability of substrates for epigenetic modifications (Frontiers in Genetics, 2021). Understanding these integrated networks is essential for the development of precision medicine strategies that can effectively target the root causes of epigenetic dysregulation.

Other names

Epigenetic crosstalkChromatin crosstalkInterplay of epigenetic modificationsEpigenetic-metabolic crosstalk

The mechanism involves the synergistic modulation of the epigenome by simultaneously targeting multiple regulatory layers, such as DNA methylation and histone acetylation, to reverse pathological gene silencing and restore normal cellular transcriptional programs (Nature Reviews Cancer, 2012).